Nonmyeloablative Allo SCT for the Treatment of Hematologic Disorders

Inclusion Criteria - Patient: * AML, ALL,CML Chronic Phase, Accelerated Phase, or Blast Crisis, CLL, MDS, RELAPSED NON-HODGKIN'S OR HODGKIN'S LYMPHOMA, Aplastic Anemia, Multiple Myeloma, MYELOPROLIFERATIVE DISORDER (P Vera, CMML, ET * Age less than 65 years * Patients must have a healthy family member who is HLA-identical to the recipient or has 1 antigen mismatch and who is willing to receive a course of G-CSF and undergo 2-4 daily leukaphereses * Each patient must sign an informed consent and be willing to participate as a research subject after having been advised of the nature and risk of the study prior to entering protocol Inclusion Criteria - Donor: * Absence of hematologic or marrow function related diseases that interferes with the collection of sufficient numbers of normal progenitor cells * Absence of any medical condition that would pose a serious health risk by undergoing peripheral blood stem cell harvest * Negative HIV, HTLV-1, Hepatitis B surface antigen and Hepatitis C * The donor must be blood relation. A prospective related donor must be at least genotypically HLA-A, B, DR identical to the patient, but can differ for 1 HLA-locus. Exclusion Criteria - Patient: * Active CNS involvement * Females who are pregnant or breast feeding * ECOG performance status \> 1. Karnofsky performance status \< 80% * LVEF \< 40% * Active viral, bacterial, or fungal infection * Patients seropositive for HIV; HTLV -1 * Patients not providing informed consent * Patients with known hypersensitivity to E. Coli derived product Exclusion Criteria - Donor: * A positive HIv infection or HTLV - 1 test or evidence of active/persistent viral hepatitis infection. Presence of any medical condition that would pose a serious health risk by undergoing peripheral blood stem cell harvest. Donors with known hypersensitivity to E. Coli derived products.